Brought to you by 
Glaucoma device developer Transcend raises $20mm Series B; closes round at $51mm
20 Jul 2011
Executive Summary
Transcend Medical, which is developing the minimally invasive stent CyPass to reduce intra-ocular pressure from glaucoma, has raised $20mm out of a potential $40mm in Series B financing, according to the Form D filing. First-time backer HLM Venture Partners led and was joined by other new investors Canaan Partners, Technology Partners, and Latterell Venture Partners. Existing shareholders Morgenthaler Ventures and Split Rock Partners also participated.
Deal Industry
- Medical Devices
-
Medical Devices
- Implantable Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Glaucoma device developer Transcend raises $20mm Series B; closes round at $51mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice